Intra-Cellular Therapies Inc. (NASDAQ:ITCI) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.33, Briefing.com reports. Intra-Cellular Therapies had a negative return on equity of 29.74% and a negative net margin of 27,180.94%. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.03 million. During the same quarter in the prior year, the company earned ($0.71) EPS. The business’s revenue was down 52.2% compared to the same quarter last year.

Intra-Cellular Therapies (ITCI) traded up 1.23% during mid-day trading on Thursday, hitting $11.56. The company had a trading volume of 25,543 shares. Intra-Cellular Therapies has a 1-year low of $7.85 and a 1-year high of $45.20. The company has a 50 day moving average of $12.00 and a 200 day moving average of $12.58. The firm’s market capitalization is $501.94 million.

Several research analysts have recently issued reports on ITCI shares. ValuEngine lowered Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Piper Jaffray Companies lowered Intra-Cellular Therapies from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $22.00 to $10.00 in a research report on Monday, May 1st. Zacks Investment Research lowered Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Cantor Fitzgerald decreased their target price on Intra-Cellular Therapies from $32.00 to $29.00 and set an “overweight” rating for the company in a research report on Tuesday, May 2nd. Finally, Ladenburg Thalmann Financial Services lowered Intra-Cellular Therapies from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $24.14.

TRADEMARK VIOLATION NOTICE: “Intra-Cellular Therapies Inc. (ITCI) Posts Quarterly Earnings Results, Beats Estimates By $0.33 EPS” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/10/intra-cellular-therapies-inc-nasdaqitci-posts-quarterly-earnings-results-beats-estimates-by-0-37-eps.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Earnings History for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.